PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
G K Khuller Selected Research
Tuberculosis
02/2008
Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles.
02/2007
Lung and blood mononuclear cell responses of tuberculosis patients to mycobacterial proteins.
10/2005
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.
06/2005
Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis.
05/2005
Human immune recognition-based multicomponent subunit vaccines against tuberculosis.
12/2004
Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis.
10/2004
Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
04/2004
Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.
12/2003
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
09/2003
Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.
04/2003
Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects.
01/2003
Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis.
10/2002
Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes.
02/2001
Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis.
02/2001
Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis.
Articles by Research Topic
Disease
15
Tuberculosis
02/2008 - 02/2001
4
Infection
07/2004 - 01/2001
Drug/Important Bio-Agent (IBA)
5
Carbon Monoxide
IBA
12/2004 - 01/2001
5
poly(lactide) (polylactide)
IBA
12/2004 - 01/2001
4
Isoniazid (Ftivazide)
FDA Link
Generic
09/2003 - 02/2001
3
Antitubercular Agents
IBA
12/2004 - 01/2001
3
Liposomes (Liposome)
IBA
04/2004 - 10/2002
3
Rifampin (Rifampicin)
FDA Link
Generic
09/2003 - 06/2001
2
Drug Carriers
IBA
10/2005 - 10/2004
2
alginic acid (sodium alginate)
IBA
10/2005 - 04/2003
2
Polyglactin 910
IBA
10/2004 - 09/2003
1
moxifloxacin (Avelox)
FDA Link
02/2008
1
Econazole
FDA Link
Generic
02/2008
1
Proteins (Proteins, Gene)
IBA
02/2007
1
Peptides
IBA
06/2005
1
Subunit Vaccines
IBA
05/2005
1
Polymers
IBA
07/2004
1
Pyrazinamide
FDA Link
Generic
09/2003
1
human neutrophil peptide 1
IBA
02/2001
Therapy/Procedure
3
Drug Therapy (Chemotherapy)
02/2008 - 06/2001